Tiragolumab in Combination with Atezolizumab Demonstrates 38% Reduction in Risk of Disease Progression as First-Line Therapy for PD-L1-Positive Metastatic NSCLC

On December 10, 2021, Genentech, a subsidiary of Roche, announced that tiragolumab, a novel cancer immunotherapy targeting TIGIT, in combination with the PD-L1 inhibitor atezolizumab, showed positive results in a Phase 2 clinical trial for the first-line treatment of patients with PD-L1-positive metastatic non-small cell lung cancer (NSCLC). At a median follow-up time of 2.5 years, the tiragolumab/atezolizumab combination demonstrated significant and sustained improvement in progression-free survival (PFS) compared to atezolizumab monotherapy.

TIGIT (T cell immunoreceptor with Ig and ITIM domains), fully named as T-cell immunoglobulin and ITIM domain protein, is an immune checkpoint protein primarily expressed on the surface of T cells and natural killer (NK) cells. The press release noted that tiragolumab is the first anti-TIGIT therapy granted Breakthrough Therapy Designation by the U.S. FDA. Blocking the TIGIT signaling pathway with tiragolumab has the potential to enhance the body's immune response to cancer cells and increase anti-tumor activity.

The latest results show that, at a median follow-up time of 2.5 years:

In the intent-to-treat (ITT) population (n=67), compared with atezolizumab monotherapy (median PFS=3.9 months), the tiragolumab/atezolizumab combination reduced the risk of disease progression or death by 38%, with a median PFS of 5.6 months (HR=0.62, 95% CI: 0.42–0.91), and improved the overall response rate (ORR) (38.8% vs. 20.6%).

Exploratory analysis in patients with high PD-L1 expression (TPS≥50%) (n=29) showed that, compared with atezolizumab monotherapy (median PFS=4.1 months), the risk of disease progression or death was reduced by 71%, with a median PFS of 16.6 months (HR=0.29, 95% CI: 0.15–0.53), and ORR was significantly improved (69% VS. 24.1%).

For the secondary endpoint of overall survival (OS) in the trial, the tiragolumab/atezolizumab combination also provided benefit to the ITT population, with a median OS of 23.2 months (14.5 months for the control group) (HR=0.69, 95% CI: 0.44–1.07).

The specific results of the experiment are shown in the table below:

Table source: Reference [1]

Dr. Levi Garraway, Chief Medical Officer and Head of Global Product Development at Roche, stated: "These encouraging results suggest that combining anti-TIGIT antibodies with anti-PD-L1 cancer immunotherapy may represent a new approach to addressing unmet needs in cancer treatment. We look forward to the results of the Phase III clinical trials in lung cancer and other challenging tumor types."

References:

[1] New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq. Retrieved December 10, 2021, from https://www.businesswire.com/news/home/20211210005111/en/New-Data-From-the-Phase-II-CITYSCAPE-Trial-Show-Encouraging-Results-With-Genentech%E2%80%99s-Novel-Anti-TIGIT-Tiragolumab-Plus-Tecentriq

▽Follow 【WuXi AppTec】Germany】WeChat Official Account